Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies.
Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families.
We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare.
To learn more, please visit http://www.neurogene.com/careers/.
Company Details
- Employees
- 107
- Founded
- -
- Address
- 535 W 24th St,
- Industry
- Biotechnology
- Website
- neurogene.com
- Keywords
- Biotechnology Research.
- HQ
- New York, New York
Neurogene Inc. Questions
Neurogene Inc.'s website is neurogene.com
Neurogene Inc.'s LinkedIn profile is https://www.linkedin.com/company/neurogeneinc
Neurogene Inc. has
107 employees.
View email and phone details for 107
employees at Neurogene Inc..
Neurogene Inc.'s industry is
Biotechnology
Neurogene Inc.'s top competitors are
Beam Therapeutics,
Allovir,
Trace Neuroscience,
Viking Therapeutics, Inc.,
Taysha Gene Therapies,
Immatics,
Nls Pharmaceutics Ag,
Kalaris Therapeutics,
Neuron23,
Cellipont Bioservices.
Neurogene Inc.'s categories are Biotechnology
Neurogene Inc.'s founding year is 2018
